| Intravenous Immunoglobulin Therapy in Peripheral Neuropathy |
| Nam Hee Kim, and Kyung Seok Park |
|
|
|
| Copyright © 2006 The Korean Society of Clinical Neurophysiology |
| This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium,
provided the original work is properly cited. |
| ABSTRACT |
|
Intravenous immunoglobulin (IVIg) is the treatment of choice for many autoimmune neuropathic disorders such as Guillain-Barre syndrome (GBS), chronic inflammatory Demyelinating neuropathy (CIDP), and multifocal motor neuropathy (MMN). IVIg is preferred because the adverse reactions are milder and fewer than the other immune-modulating methods such as steroid, other immunosuppressant such as azathioprine, and plasmapheresis. IVIg also has beenused in other autoimmune neuromuscular disorders (inflammatory myopathy, myasthenia gravis, and Lambert-Eaton myasthenic syndrome) and has been known as safe and efficient agent in these disorders. Since IVIg would get more indications and be used more commonly, clinicians need to know the detailed mechanism of action, side effects, and practical points of IVIg. |
| Key words:
Intravenous Immunoglobulin (IVIg), Neuropathy, Autoimmune diseases, Guillain-Barre syndrome, Chronic inflammatory demyelinating neuropathy, Multifocal motor neuropathy |
|
|
|
PDF Links
Download Citation 
Print 
